Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 12/20 | 0.59 |
| ▸ | CHRNA3 | P32297 | 12/20 | 0.59 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24344048 | 0.86 | CHRNA7 (0.68) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 | |
| SCHEMBL17821122 | 0.78 | CHRNA7 (0.54) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 | |
| SCHEMBL17864140 | 0.78 | CHRNA7 (0.54) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 | |
| SCHEMBL2807123 | 0.74 | CHRNB4 (0.90) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 | |
| SCHEMBL13114823 | 0.74 | ALDH1A1 (0.60) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 | |
| SCHEMBL25348846 | 0.72 | CYP2A6 (0.44) | CHRNB4CHRNA3CYP2A6PTK2CYP11B1 | |
| SCHEMBL2045328 | 0.72 | CHRNB4 (0.57) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 | |
| SCHEMBL14392676 | 0.72 | CYP2A6 (0.61) | CYP2A6PTK2CYP11B1CYP11B2PTGS2 | |
| Hydrochloric Acid SCHEMBL1418507 | 0.71 | CHRNA7 (0.59) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 | |
| SCHEMBL14993852 | 0.71 | CYP2A6 (0.47) | CHRNB4CHRNA3CYP2A6PTK2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11712467-B2 | Methods of rational nicotine hapten design and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2023-08-01 | — | — | US | disclosed |
| US-11712467-B2 | Methods of rational nicotine hapten design and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2023-08-01 | — | — | US | disclosed |
| US-11712467-B2 | Methods of rational nicotine hapten design and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2023-08-01 | — | — | US | disclosed |
| EP-4119671-A1 | METHOD FOR SYNTHESIZING (S)-NICOTINE | Porton Pharma Solutions Ltd. (CN) | 2023-01-18 | — | — | EP | disclosed |
| US-20220362375-A1 | METHODS OF RATIONAL NICOTINE HAPTEN DESIGN AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-11-17 | — | — | US | disclosed |
| US-11357848-B2 | Methods of rational nicotine hapten design and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2022-06-14 | — | — | US | disclosed |
| US-11357848-B2 | Methods of rational nicotine hapten design and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2022-06-14 | — | — | US | disclosed |
| US-20180125969-A1 | METHODS OF RATIONAL NICOTINE HAPTEN DESIGN AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2018-05-10 | — | — | US | disclosed |
| US-20180125969-A1 | METHODS OF RATIONAL NICOTINE HAPTEN DESIGN AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2018-05-10 | — | — | US | disclosed |
| US-20180125969-A1 | METHODS OF RATIONAL NICOTINE HAPTEN DESIGN AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2018-05-10 | — | — | US | disclosed |
| US-9884114-B2 | Methods of rational nicotine hapten design and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884114-B2 | Methods of rational nicotine hapten design and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884114-B2 | Methods of rational nicotine hapten design and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-02-06 | — | — | US | disclosed |
| US-20160375131-A1 | METHODS OF RATIONAL NICOTINE HAPTEN DESIGN AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2016-12-29 | — | — | US | disclosed |
| US-20160375131-A1 | METHODS OF RATIONAL NICOTINE HAPTEN DESIGN AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2016-12-29 | — | — | US | disclosed |
| US-20100260671-A1 | COMPOUNDS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF AMYLOID ASSOCIATED DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100260671-A1 | COMPOUNDS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF AMYLOID ASSOCIATED DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-10-14 | — | — | US | disclosed |
| WO-2008151073-A1 | COMPOUNDS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF AMYLOID ASSOCIATED DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-12-11 | — | — | WO | disclosed |
| WO-2002058635-A2 | NICOTINE IMMUNOGENS AND ANTIBODIES AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220362375-A1 | METHODS OF RATIONAL NICOTINE HAPTEN DESIGN AND USES THEREOF | NAPRT, CHRNG, CHRNB2 | CHRNB4 5/4885CHRNA3 13/4885CHRNA7 12/4885 |
| US-11712467-B2 | Methods of rational nicotine hapten design and uses thereof | NAPRT, CHRNG, CHRNB2 | CHRNB4 5/4885CHRNA3 13/4885CHRNA7 12/4885 |
| US-20100260671-A1 | COMPOUNDS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF AMYLOID ASSOCIATED DISEASES | APP, HTT, SCN3A | CHRNB4 25/4885CHRNA3 5/4885CHRNA7 42/4885 |
| US-20160375131-A1 | METHODS OF RATIONAL NICOTINE HAPTEN DESIGN AND USES THEREOF | NAPRT, CHRNG, CHRNB2 | CHRNB4 5/4885CHRNA3 13/4885CHRNA7 12/4885 |
| US-11357848-B2 | Methods of rational nicotine hapten design and uses thereof | NAPRT, CHRNG, CHRNB2 | CHRNB4 5/4885CHRNA3 13/4885CHRNA7 12/4885 |
| US-20180125969-A1 | METHODS OF RATIONAL NICOTINE HAPTEN DESIGN AND USES THEREOF | NAPRT, CHRNG, CHRNB2 | CHRNB4 5/4885CHRNA3 13/4885CHRNA7 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.